# Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Study · id `cardio:ct-nct01897532` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01897532](<https://clinicaltrials.gov/study/NCT01897532>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01897532

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6991 participants.

## Technical summary

Registry record NCT01897532. Randomized; double masking; primary purpose treatment. Start 2013-07-10 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-01-25.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 6991 participants (enrolled count; ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Started: 2013-07-10 (actual) (ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Primary completion: 2018-01-18 (actual) (ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Completion: 2018-01-18 (actual) (ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Results first posted: 2019-01-25 (ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Germany; Hungary; Israel; Japan; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Russia; South Africa; South Korea; Spain; Taiwan; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01897532, source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01897532-2019-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Linagliptin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial (`cardio:pubmed-30418475`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA (`cardio:pubmed-30586723`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial (`cardio:pubmed-31399442`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (`cardio:pubmed-32444457`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cfe1bd91fff8b2f93ab732d42007b5636494d73b1bc2686fda9089fe57c57842
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
